4//SEC Filing
Topper David Joseph 4
Accession 0001787306-24-000133
CIK 0001787306other
Filed
Sep 24, 8:00 PM ET
Accepted
Sep 25, 9:42 PM ET
Size
7.4 KB
Accession
0001787306-24-000133
Insider Transaction Report
Form 4
Topper David Joseph
Chief Financial Officer
Transactions
- Award
Common Stock
2024-09-21+60,000→ 170,000 total - Sale
Common Stock
2024-09-24$9.48/sh−11,626$110,264→ 158,374 total
Footnotes (3)
- [F1]Represents Performance Stock Units ("PSUs"), initially granted on June 20, 2024, in which the shares were subject to a performance-based vesting condition, which was deemed satisfied on September 21, 2024 (the "Vesting Commencement Date"). Therefore, 50% of the shares vested on September 21, 2024 and the remaining 50% of the shares vest on September 21, 2025, subject to the Reporting Person's continued service with the Company through the applicable vesting date.
- [F2]Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the PSUs, the shares were sold upon the vesting of the PSUs solely to cover applicable tax withholding.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.40 to $9.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Arcutis Biotherapeutics, Inc.
CIK 0001787306
Entity typeother
Related Parties
1- filerCIK 0001740378
Filing Metadata
- Form type
- 4
- Filed
- Sep 24, 8:00 PM ET
- Accepted
- Sep 25, 9:42 PM ET
- Size
- 7.4 KB